Just a moment...
Press 'Enter' to add multiple search terms. Rules for Better Search
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
Tokyo, Sep 22 (AP) Wall Street veered toward losses on early Monday following another record-setting week that was propelled by the Federal Reserve's first interest rate cut of the year.
Futures for the S&P 500 shed 0.3 per cent before the bell, while futures for the Nasdaq and Dow Jones Industrial Average each fell 0.4 per cent.
The Fed's rate cut last week has raised optimism on Wall Street that the US central bank would keep lowering its benchmark lending rate to close out 2025, giving the economy extra fuel.
Fed Chair Jerome Powell said the central bank may have to react quickly because recent data have shown that the US labour market is not as strong as previously thought. Complicating the matter is inflation, which remains stubbornly high, possibly a byproduct of President Donald Trump's tariffs.
Markets have largely shrugged off the latest inflation data, instead focusing more on the rate cuts it's expected to trigger.
“Every time the market seems to be running out of momentum, it fools most of us by pushing to higher heights,” said Jay Woods, chief market strategist at Freedom Capital Markets.
“As traders continue to monitor new highs on a daily basis, they are really focused on what Fed officials will have to say as they make the speaking rounds this week.” New Trump Fed appointee Stephen Miran will outline his economic and policy views at the Economic Club of New York later Monday. Powell is scheduled to speak about the U.S. economic outlook in Providence, Rhode Island, on Tuesday.
In equities trading early Monday, T-Mobile shares slipped 1.2 per cent after the telecom announced that Chief Operating Officer Srini Gopalan would replace Mike Sievert as CEO. Sievert was appointed to a newly created management position at the company.
Pfizer shares dipped 1.6 per cent after it said it would spend $ 4.9 billion to acquire the development-stage obesity drugmaker Metsera. Metsera has no products on the market, but its pipeline includes four programs in clinical development and one in midstage testing.
In Europe, France's CAC 40 slipped 0.1 per cent at midday, while the German DAX lost 0.6 per cent. Britain's FTSE 100 inched up less than 0.1 per cent.
Earlier in Asia, Japan's benchmark Nikkei 225 jumped 1.0 per cent to finish at 45,493.66, rebounding from the decline late last week over concerns about the Bank of Japan's selling its holdings. Such concerns abated as markets began to see any move as gradual.
Australia's S&P/ASX 200 rose 0.4 per cent to 8,810.90. South Korea's Kospi gained 0.7 per cent to 3,468.65. Hong Kong's Hang Seng slipped 0.8 per cent to 26,344.14, while the Shanghai Composite rose 0.2 per cent to 3,828.58. (AP) SKS SKS